Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News
Financial Results · Q3 2026

Mineralys Therapeutics Q3 2026 Results: Net Loss of $57.3M, Loss Widens

Mineralys Therapeutics reported a net loss of $337.7 million for the nine months ended September 30, 2026, driven by a $200 million upfront license amendment payment and increased R&D and G&A expenses. The company ended the period with $624.7 million in cash, cash equivalents, and investments, and is awaiting an FDA decision on its NDA for lorundrostat with a PDUFA date of December 22, 2026.

Q3 2026 at a glance · $ million
MetricQ3 2026Q3 2025
Net income-57.3-36.9
EPS (diluted, $ a share)$-0.64$-0.52

A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.

Source

10-Q filed with the SEC, NASDAQ: MLYS. Figures from the filing's XBRL data; summary written with AI assistance from the filing.

Read the filing ↗

Mineralys Therapeutics, Inc.: key numbers

Share price
$14.53Close, Nov 16
Market cap
$1.29B
Shares outstanding
88.56MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers, updated daily. Not a valuation or a recommendation.

More from Mineralys Therapeutics, Inc.

All →
4:10 PM ET 8-K
Financial Results

Mineralys Therapeutics Financial Results

Mineralys Therapeutics reported Q3 2026 financial results and provided a corporate update regarding its lead candidate, lorundrostat, which has a PDUFA target date of December 22, 2026. The company also announced the resignation of board member Derek DiRocco, Ph.D., effective December 31, 2026.

“With approximately 20 million adults in the U.S. living with uncontrolled or resistant hypertension, despite treatment, there is a significant need for new treatment options. As we approach the December 22nd PDUFA target date for lorundrostat, our focus is on completing our launch preparations so that we are ready to reach patients quickly, pending approval.”

Jon Congleton, Chief Executive Officer of Mineralys

“We continue to receive positive feedback from providers, payers and people living with hypertension, and we look forward to the potential to bring lorundrostat to millions of patients in need.”

Jon Congleton, Chief Executive Officer of Mineralys
4:08 PM ET 8-K
M&A Deal

Mineralys Therapeutics M&A Deal with Tanabe Pharma Corporation

Mineralys Therapeutics entered into a Termination Agreement and Payment Obligation Agreement with Tanabe Pharma Corporation to acquire full ownership of the intellectual property for lorundrostat. The agreements terminate the existing license and assign the patents and know-how directly to Mineralys, while maintaining existing commercial milestone obligations of up to $265 million. This transition from licensee to owner removes potential change-of-control payment triggers and consolidates the company's control over its lead drug candidate.

Counterparty
Tanabe Pharma Corporation
4:37 PM ET 8-K
Leadership Change

Mineralys Therapeutics Leadership Change

Mineralys Therapeutics appointed Kristine Peterson and Lonnel Coats to its Board of Directors, effective October 19, 2026, increasing the board size from seven to nine members. Both new directors will receive standard non-employee director compensation, including initial grants of 16,600 stock options and 12,400 restricted stock units each.

5:53 PM ET Form 4
Insider Selling

Mineralys Therapeutics CEO Jon Congleton Sells $1.91M of Stock

Jon Congleton, CEO, sold 75,000 shares of Mineralys Therapeutics, Inc. at $25.46 a share, worth $1.91M in total on Sep 30, 2026. Shares held after the trade: 528,621 (-12.4%).

Value
$1.91M
Shares
75,000
Price
$25.46
Role
CEO
Holding change
-12.4%
Trade date
Sep 30, 2026
9:50 PM ET Form 4
Insider Selling

Mineralys Therapeutics Insider Brian Taylor Slingsby Sells $3.01M of Stock

Brian Taylor Slingsby sold 104,320 shares of Mineralys Therapeutics, Inc. at $28.81 a share, worth $3.01M in total on Sep 22, 2026. Shares held after the trade: 7,805,718 (-1.3%).

Value
$3.01M
Shares
104,320
Price
$28.81
Holding change
-1.3%
Trade date
Sep 22, 2026

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.